Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy
– First Clinical Study of a Central Nervous System-Administered RNAi Therapeutic Showed Rapid and Robust Target Engagement with Sustained Effect Over 6 Months with a Single Dose – – ALN-APP Continues to Demonstrate an Encouraging Clinical Safety and Tolerability Profile – – Multiple-dose Portion of Study, Part B, Being Initiated in Approved Regions –
Source: marketscreener.com
